CDK4/6 inhibitors: a novel strategy for tumor radiosensitization by Yilan Yang, Jurui Luo, Xingxing Chen, Zhaozhi Yang, Xin Mei, Jinli Ma, Zhen Zhang, Xiaomao Guo, Xiaoli Yu

Subjects: “…CDK4/6 inhibitor…”
Get full text

Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2– advanced breast cancer by Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li, Binghe Xu

Subjects: Get full text

Palbociclib in the treatment of recurrent ovarian cancer by Dai Wee Lee, Gwo Fuang Ho

Subjects: Get full text

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer by Xiang Zhu, Xiaojie Xu, Lin Zhang, Xuhui Yang

Subjects: Get full text

Enhancing immunogenic responses through CDK4/6 and HIF2α inhibition in Merkel cell carcinoma by Jung Hyun Lee, Justin Daho Lee, Kelly Paulson, Valentin Voillet, Andre Berndt, Candice Church, Kristina Lachance, Song Y. Park, Naomi K. Yamamoto, Elizabeth A. Cromwell, Raphael Gottardo, Aude G. Chapuis, Paul Nghiem

Subjects: “…CDK4/6 inhibitor…”
Get full text

Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma by Songlin Liu, Dun Yuan, Yifeng Li, Qi Qi, Bingzhong Guo, Shun Yang, Jilin Zhou, Lu Xu, Tiange Chen, Chenxing Yang, Junyu Liu, Buyan Li, Li Yao, Weixi Jiang

Subjects: Get full text

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials by Linghong Guo, Yuanyuan Hu, Xi Chen, Qingfang Li, Benling Wei, Xuelei Ma

Subjects: “…CDK 4/6 inhibitor…”
Get full text

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-e... by Merve Keskinkilic, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, Ilhan Oztop

Subjects: Get full text

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B) by Hiroko Masuda, Yuko Tanabe, Hitomi Sakai, Koji Matsumoto, Akihiko Shimomura, Mihoko Doi, Yasuo Miyoshi, Masato Takahashi, Yasuaki Sagara, Shinya Tokunaga, Tsutomu Iwasa, Naoki Niikura, Kenichi Yoshimura, Toshimi Takano, Junji Tsurutani

Subjects: “…CDK4/6 inhibitor…”
Get full text

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature by Steven David, Gwo Ho, Daphne Day, Marion Harris, Jennifer Tan, Shom Goel, Gerard G. Hanna, Ranjana Srivastava, Gill Kruss, Lachlan McDowell, Michelle White

Subjects: “…CDK 4/6 inhibitor…”
Get full text

The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials by Jingyue Qiu, Dandan Sheng, Fei Lin, Fei Lin, Peng Jiang, Ning Shi

Subjects: “…CDK4/6 inhibitor…”
Get full text

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database by Jinhua Chen, Linlin Tang, Wenping Song, Cuicui Sun, Wenzhou Zhang

Subjects: “…CDK4/6 inhibitor…”
Get full text

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer by Xi Jin, Li-Ping Ge, Da-Qiang Li, Zhi-Ming Shao, Gen-Hong Di, Xiao-En Xu, Yi-Zhou Jiang

Subjects: Get full text

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest by Jiayuan Wang, Qingqing Li, Jiajia Yuan, Jingyuan Wang, Zuhua Chen, Zhentao Liu, Zhongwu Li, Yumei Lai, Jing Gao, Lin Shen

Subjects: “…CDK4/6 inhibitor…”
Get full text

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) by A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

Subjects: Get full text

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma by Yuan Ke, Cheng-Gong Liao, Zheng-Qing Zhao, Xiao-Min Li, Rong-Jie Lin, Long Yang, He-Long Zhang, Ling-Min Kong

Subjects: “…CDK4/6 inhibitor…”
Get full text

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgro... by Paul Cottu, Alistair Ring, Hikmat Abdel-Razeq, Paolo Marchetti, Fatima Cardoso, Javier Salvador Bofill, Miguel Martín, Lakshmi Menon-Singh, Jiwen Wu, Michelino De Laurentiis

Subjects: Get full text

CDK4/6 inhibitor resistance: A bibliometric analysis by Jiayuecheng Pang, Hengyu Li, Yuan Sheng

Subjects: “…CDK4/6 inhibitor…”
Get full text

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literat... by Yan Mao, Meng Lv, Yongmei Wang, Weihong Cao, Wenfeng Li

Subjects: “…CDK4/6 inhibitor…”
Get full text

Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review by Nuno Rodrigues Alves, Nuno Rodrigues Alves, Ana Filipa Duarte, Ana Filipa Duarte, Ana Filipa Duarte, David Fernandes Ribeiro, Rita Sousa Silva, Rita Sousa Silva, Rita Sousa Silva, Bruno Almeida Carvalho, Bruno Almeida Carvalho, Diogo Alpuim Costa, Diogo Alpuim Costa, Diogo Alpuim Costa, Diogo Alpuim Costa

Subjects: “…CDK4/6 inhibitor…”
Get full text